



Tennessee Oncology Pharmacist Association 5th Annual Meeting

November 4, 7, 11 & 14, 2020

via Zoom

All times are Central Standard Time

Open to All Oncology Professionals

Up to 9.0 contact hours (0.9 CEUs) of live ACPE Pharmacy CE Credit Available
for these Knowledge-based Activities

[Register Here](#)

Deadline to Register: November 2, 2020

Registration Fees

\$75 - Non-Members & Industry Professionals

Free for TOPA Members, Residents, and Students

Free for Friends of TOPA (No CE credit)

Requirements for Successful Completion: These knowledge-based activities for pharmacists will provide up to 9.0 contact hours (0.9 CEUs) of live continuing education credit to pharmacists who attend the seminar(s) in entirety, participate in active learning, and complete the activity evaluation for each seminar attended no later than Wednesday, November 25, 2020.



Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CPE event is jointly provided with the Tennessee Oncology Pharmacists Association.

Questions? Email tnoncpharm@gmail.com

Program Agenda

Wednesday, November 4, 2020

1:45-2:00 (CST)

Welcome

Mona Benashid, PharmD, BCOP, TOPA Board President

2:00-2:30pm

Hemophilia Treatment: Factors to Consider (0.05 CEU, UAN: 0863-9999-20-078-L01-P)

Patricia J. "PJ" Barker, PharmD, BCPPS, *Clinical Coordinator, St. Jude Children's Research Hospital, Memphis, TN*

Dr. Barker has no relevant financial relationships to disclose.

Learning Objectives

1. Discuss standard half life and extended half life factor treatment options for patients with hemophilia
2. Describe emicizumab-kxwh's role in therapy for Hemophilia A

2:30-3:30pm

Pharmacogenomics in Oncology (0.1 CEU, UAN: 0863-9999-20-086-L01-P)

Cyrine Haidar, PharmD, BCPS, BCOP, *Assistant Professor, University of Tennessee Health Science Center, College of Pharmacy, Memphis TN & Clinical Pharmacogenetics Coordinator, St. Jude Children's Research Hospital, Memphis, TN*

Dr. Haidar has no relevant financial relationships to disclose.

Learning Objectives

1. Demonstrate an understanding of the role some pharmacogenes play in the selection and dosing of chemotherapy regimen
2. Describe how pharmacogenomic testing can help in the supportive care management of patients with cancer

3:30-4:00pm

Adapting to Payer Changes for Clinic-Administered Medications

(0.05 CEU, UAN: 08630863-9999-20-079-L04-P)

Garrett Crothers, PharmD, MBA, BCPS, *Program Director, Special Projects, Vanderbilt University Medical Center, Nashville, TN*

Dr. Crothers has no relevant financial relationships to disclose.

Learning Objectives

1. Recognize payer strategies to reduce the cost of clinic-administered therapies
2. Describe challenges associated with brown bagging, white bagging, and clear bagging
3. Identify operational strategies utilized at other institutions for applicability within one's own practice

4:00pm

Closing Remarks

Mona Benashid, PharmD, BCOP, TOPA Board President

Program Agenda (continued)

Saturday, November 7, 2020

8:45-9:00am (CST)

Welcome

Mona Benashid, PharmD, BCOP, TOPA Board President

9:00-10:00am

GU Oncology: So Much to Know and So Little Time to Know It (Before Something New Gets Approved)

(0.1 CEU, UAN: 0863-9999-20-089-L01-P)

Renee McAlister, PharmD, BCOP, *Oncology Clinical Pharmacy Specialist, Melanoma and GU Oncology Clinics, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN*

Dr. McAlister has no relevant financial relationships to disclose.

Learning Objectives

1. Recall recent FDA approvals for treatment of genitourinary (GU) malignancies
2. Summarize new practice-changing literature for treatment of GU malignancies
3. Recognize recent guideline updates for treatment of GU malignancies
4. Describe integration of new approvals into clinical practice

10:00-11:00am

New Drug Update (0.1 CEU, UAN: 0863-9999-20-080-L01-P)

Brendan L. Mangan, PharmD, *Clinical Pharmacy Specialist-Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA*

Dr. Mangan has no relevant financial relationships to disclose.

Learning Objectives

1. Explain the pharmacology of each new medication
2. Define indications, adverse effects and pertinent drug interactions
3. Outline supportive care measures and clinical pearls
4. Discuss the results of clinical trials and place in therapy

11:00am-12:00pm

New Developments in the Management of HER2+ and Triple-Negative Breast Cancer

(0.1 CEU, UAN: 0863-9999-20-081-L01-P)

Dennis Marjoncu, PharmD, BCOP, *Hematopoietic Cell Transplantation clinical Pharmacy Specialist, Methodist University, Memphis, TN*

Dr. Marjoncu has no relevant financial relationships to disclose.

Learning Objectives

1. Recognize the prognostic factor implications of HER2+ and triple-negative breast cancer
2. Describe the literature for new agents and agents with expanded indications in breast cancer
3. Translate information gathered from new trials to patient case scenarios

12:00pm

Closing Remarks

Mona Benashid, PharmD, BCOP, TOPA Board President

Questions? Email tnoncpharm@gmail.com

Program Agenda (continued)

Wednesday, November 11, 2020

1:45-2:00pm (CST)

Welcome

Mona Benashid, PharmD, BCOP, TOPA Board President

2:00-2:30pm

Impact of COVID-19 on Oncology Care (0.05 CEU, UAN: 0863-9999-20-090-L01-P)

Heather Nelkin, PharmD, BCOP, *System Manager, Investigational Drug Services, Novant Health*
Dr. Nelkin has no relevant financial relationships to disclose.

Learning Objectives

1. Appraise guideline updates that impact oncology care during COVID-19 Pandemic
2. Recognize practice changes implemented to protect cancer patients during COVID-19
3. Identify impacts to oncology research trials during COVID-19

2:30-3:30pm

Updates in Thoracic Oncology (0.1 CEU, UAN: 0863-9999-20-085-L01-P)

Amanda Cass, PharmD, BCPS, BCOP, *Clinical Pharmacy Specialist - Thoracic Oncology, Vanderbilt University Medical Center, Nashville, TN*
Dr. Cass is an Advisory Board Member for Novartis for capmatinib.

Learning Objectives

1. Recall the pathophysiology of lung cancer and mesothelioma
2. Discuss pharmacotherapy options for treatment of lung cancer and mesothelioma
3. Summarize new literature in the treatment of lung cancer and mesothelioma
4. Recognize updates to NCCN guidelines for treatment of lung cancer and mesothelioma

3:30-4:00pm

Nucleic Acid-Based Diagnostic Techniques in Malignancy (0.05 CEU, UAN: 0863-9999-20-082-L01-P)

Ryan M. Miller, PharmD, BCOP, *Clinical Pharmacy Specialist— Adult Malignant Hematology, Vanderbilt University Medical Center, Nashville, TN*
Dr. Miller has no relevant financial relationships to disclose.

Learning Objectives

1. Differentiate between the different applications of NGS
2. Explain the differences between Sanger Sequencing and Next Generation Sequencing (NGS)
3. Evaluate the pros and cons of utilizing circulating tumor DNA in solid tumors

4:00pm

Closing Remarks

Mona Benashid, PharmD, BCOP, TOPA Board President

Program Agenda (continued)

Saturday, November 14, 2020

8:45-9:00am (CST)

Welcome

Mona Benashid, PharmD, BCOP, TOPA Board President

9:00-9:30am

The Art of Giving Feedback: How to Give Feedback that Improves Performance

(0.05 CEU, UAN: 0863-9999-20-083-L04-P)

Jennifer Pauley, PharmD, BCPS, BCOP, *Clinical Coordinator, Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN*

Dr. Pauley has no relevant financial relationships to disclose.

Learning Objectives

1. Explain the importance of feedback
2. Recognize examples of effective and ineffective feedback
3. Recall tools to improve feedback

9:30-10:30am

Eyes on the Target: Updates in the Treatment of Chronic Lymphocytic Leukemia

(0.1 CEU, UAN: 0863-9999-20-084-L01-P)

Gregory T. Sneed, PharmD, *Assistant Professor, Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Memphis, TN*

Dr. Sneed has no relevant financial relationships to disclose.

Learning Objectives

1. Describe the pathophysiology of Chronic Lymphocytic Leukemia (CLL)
2. Explain pharmacotherapy options used in the treatment of CLL
3. Interpret data from recent trials in the treatment of CLL
4. Apply knowledge of CLL treatment to patient-specific clinical scenarios

10:30-11:00am

New Options for Relapsed & Refractory Osteosarcoma *(0.05 CEU, UAN: 0863-9999-20-087-L01-P)*

Anthony "Andy" Christensen, PharmD, BCOP, *Clinical Pharmacy Specialist - Pediatric Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN*

Dr. Christensen has no relevant financial relationships to disclose.

Learning Objectives

1. Describe the outcomes of patients with relapsed osteosarcoma treated with conventional cytotoxic chemotherapy
2. Outline the impact of regorafenib and cabozantinib for patients with relapsed osteosarcoma

11:00am

Closing Remarks

Mona Benashid, PharmD, BCOP, TOPA Board President

Technology Requirements

Belmont University Policy on Privacy & Confidentiality: [Belmont University Information Technology Policies](#)

- Zoom System Requirements: [For iOS, iPadOS, and Android](#) [For Windows, macOS, and Linux](#)
- Zoom app that can be [downloaded](#) from the Zoom website for computers or on mobile devices through the App Store or Google Play. Search for Zoom Cloud Meetings app.
- If planning to use a MacBook, Macbook Pro, MacBook Air, iMac, etc., please navigate to <https://zoom.us/> (using the Mac computer that will be used for the Zoom session), click on the Download link a the right side of the screen, download and install/run the installer program (named Zoom.pkg).
- Please refer to the following webpages to troubleshoot any audio/visual difficulties
 - <https://support.zoom.us/hc/en-us/articles/206175806-Frequently-Asked-Questions>
 - <https://support.zoom.us/hc/en-us/articles/201362283-How-Do-I-Join-or-Test-My-Computer-Audio->
 - <https://support.zoom.us/hc/en-us/articles/201362313-How-Do-I-Test-My-Video>
- A computer with a stable internet connection
- A webcam—built-in or external attachment—and have video enabled throughout the entire program
- A microphone & speakers/headphones to join via computer audio or a phone to join via phone audio. For computer audio: The use of headphones will reduce an echo or feedback.
- If you experience technical issues during a presentation, please notify the meeting host via the chat box as soon as possible and/or send an email to pharmacyce@belmont.edu.

Claiming CE Credit

Each presentation will be conducted online using the Belmont University Zoom account. To participate & be eligible for CE credit, each learner must:

- Join Zoom Meeting (video & audio) by computer, tablet, or any mobile device.
 - Join the meeting 15-30 minutes early to test that your Zoom connection, audio, video, and app functionality are working properly and to check in
 - Zoom Meeting links will be emailed to registered learners 1-2 business days prior to each program day. Note that each day of the program is a different link.
- Log in individually. Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. CE credit is earned by one attendee per device.
- Once in the Meeting, rename yourself to your First Name & Last Name. For example, “Bob’s iPad” should be renamed “Bob Smith.” To rename yourself, click “More” by your name in the Participant List and click “Rename.”
- Attend the entirety of each presentation to be eligible for CE credit for each presentation. Learners who join late or sign off early will not be eligible for CE credit.
- Actively participate in the Zoom poll questions & discussions for each presentation. Use the Chat Box to send questions/ comments to everyone or to an individual.
- Minimize distractions (e.g., background noise, other people in the room).
- Complete the corresponding electronic evaluation for each presentation attended to claim CE credit.

Instructions for claiming CE credit for each presentation will be emailed to eligible learners 1-2 business days following each webinar. “Eligible learner” is defined as a learner who is present (logged in) for the presentation for its entirety AND actively participates in the active learning segments (i.e., polling questions). Registration reports will be compared to day-of Zoom reports to verify those who registered **and** attended the entire presentation **and** participated in active learning.

NABP e-profile ID: Your CE credits will be automatically submitted to NABP CPE Monitor upon completion of the online activity evaluation. Questions regarding your NABP e-Profile or CPE Monitor? www.nabp.net/programs/cpe-monitor/cpe-monitor-service.

If your pharmacy CE credit has not posted after 48 hours from submission date, please contact pharmacyce@belmont.edu for assistance.